Avails Medical announces the commencement of U.S. Pivotal Clinical Trials for eQUANTâ„¢
Retrieved on:
Monday, August 15, 2022
MENLO PARK, Calif., Aug. 15, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (eAST) announced today the commencement of U.S. pivotal clinical trials for its eQUANTsystem, which will be used to support a submission for FDA clearance.
Key Points:
- MENLO PARK, Calif., Aug. 15, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (eAST) announced today the commencement of U.S. pivotal clinical trials for its eQUANTsystem, which will be used to support a submission for FDA clearance.
- In a recent clinical pilot study Avails demonstrated highly accurate AST results when using the eQUANT McFarland output.
- "Our modular, cost-efficient eQUANT system features a small footprint and straight-forward user interface, making it well suited for widespread adoption from clinical laboratories to community hospitals.
- Avails Medical, Inc., a privately held company, was founded to help fight one of today's biggest global health threats - antibiotic resistance.